Followers | 229 |
Posts | 14579 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
Thursday, March 08, 2018 6:24:02 PM
If the blinded data, which should present the treatment and control arm data together as if this were a single arm trial, is impressively better than any other present GBM data (especially for any approved treatment like the electronic helmet one, who's current median OS for their treatment patients indicates 20 months), then the market should realize that the unblinded data for DCVax-L will trend even higher for their treatment arm.
That alone should impress the market.
Ultimately, the purpose for those in the market is to make money. Once the market realizes it can make money in $NWBO... with a P3 trial for GBM based on information indicating efficacy, albeit by non-traditional fundamentals (blinded, blended data for now), the market will begin to pile in, especially at these pathetically low prices.
And if there is a large naked short contingency, they will ultimately be forced to correct. If there's not, then $NWBO will rise more slowly on its own momentum.
And let's not forget the GMB patients in this tale.
If someone is diagnosed with GBM and they google their cancer and this abstract for DCVax-L pops up indicating perhaps really good blinded data... data that may be music to their ears, these patients and their families will start converging on the FDA demanding quick approval.
So I'll end this post with something tasty to chew on, and that is "it's hard to hide something everyone is looking for."
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM